Acteoside

DB12996InvestigationalSmall molecule

Acteoside is under investigation in clinical trial NCT02662283 (Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy).

Chemical structure of Acteoside
Formula / weight
C29H36O15 · 624.5871 g/mol (avg)
Code names
TJC-160

Resolves to

Compound
UNII3TGX09BD5BCAS61276-17-3ChEMBLCHEMBL444478ChEBI132853PubChem5281800KEGGC10501
Structure
InChIKeyFBSKJMQYURKNSU-ZLSOWSIRSA-NSMILESC[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCC3=CC(O)=C(O)C=C3)O[C@H](CO)[C@H]2OC(=O)\C=C\C2=CC(O)=C(O)C=C2)[C@H](O)[C@H](O)[C@H]1O
Targets
P17252PRKCA

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
400Drug interactionsStructured to mechanism, not free text
Sign in
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Acteoside, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In